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ABSTRACT: Interferons (IFNs) are now known to exert a multitude of im-
munological functions on both the innate and adaptive immunity. Given
their pleiotropic effects on the immune system, it is conceivable that ex-
cess type I IFN or aberrant regulation of its signaling could contribute to
autoimmunity. Several lines of evidence link IFNs to autoimmune disor-
ders, in particular to systemic lupus erythematosus (SLE) and systemic
sclerosis (SSc). Expression of a spectrum of genes that constitutes an
“IFN signature” is the most significant observation indicating that IFNs
may be dominant among the pathogenic mediators involved in some au-
toimmune diseases. A family of IFN-inducible genes, designated HIN-200
in the human and IFI-200 in the murine species, encodes evolutionary re-
lated human (IFI16, MNDA, AIM2, IFIX) and murine proteins (Ifi202 a,
Ifi202b, Ifi203, Ifi204, Ifi205/D3). Physiological IFI16 expression was
found in cells of the immune system, in endothelial cells, and in stratified
squamous epithelia, such as skin. The presence of anti-IFI16 antibodies
was reported in SLE and primary/secondary Sjo¨gren’s syndrome. More
recently, we reported that anti-IFI16 autoantibodies differentiate lim-
ited cutaneous systemic sclerosis (lcSSc) from diffuse systemic sclerosis
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(dcSSc). Molecular studies performed in primary endothelial cells over-
expressing IFI16 demonstrated that it may be involved in the early steps
of inflammation by modulating endothelial cell function, such as expres-
sion of adhesion molecules and chemokine production, cell growth, and
apoptosis. Moreover, here we report that IFI16 expression is induced by
proinflammatory cytokines. In this article the role of the IFI16 protein
and its corresponding autoantibodies in the etiopathogenesis of systemic
autoimmune diseases, in which chronic inflammation is involved, are
discussed.
KEYWORDS: autoimmunity; systemic sclerosis; SSc; systemic lupus ery-
thematosus; SLE; interferon-inducible gene IFI16; inflammation
INTRODUCTION
Systemic sclerosis (SSc, scleroderma) is a generalized connective tissue dis-
order of unknown etiology, characterized by a wide spectrum of microvascular
and immunological abnormalities, leading to progressive thickening and fibro-
sis of the skin and visceral organs, including the lung, heart, gastrointestinal
tract, and kidney. Patients with SSc express a variety of autoantibodies that have
their own clinical association. Disease heterogeneity and difficulties separating
SSc from SSc-like conditions make classification an important issue. Accord-
ing to the criteria of LeRoy et al.,1 established in 1988, SSc can be classified
into two major subsets, on the basis of the extent of skin thickening: one char-
acterized by diffuse skin fibrosis with more severe internal organ involvement
(dcSSc), the other with limited cutaneous involvement (lcSSc). lcSSc and dc-
SSc, with different severity and survival, have been recognized for several years
as distinct subsets. This issue remains unsettled, but transition from one to the
other is seldom seen, which could favor the former interpretation. Importantly,
the two classical SSc-selective autoantibodies segregate clearly between the
subsets, lcSSc being associated with anticentromere (ACA), and dcSSc with
antitopoisomerase I (Scl70) antibodies. The lcSSc/dcSSc classification has
now been widely accepted and used in numerous clinical studies and thera-
peutic trials.
Several lines of evidence link the interferons (IFNs) to autoimmune dis-
orders, in particular to SSc and systemic lupus erythematosus (SLE). Serum
levels of IFN- are elevated in active SLE, and therapeutic IFN- has oc-
casionally been noted to induce lupus autoantibodies and even clinical SLE.
Finally, the prominent role of IFNs in the hierarchy of immune system media-
tors involved in SSc and SLE has been demonstrated by data from analyses of
gene expression in peripheral blood mononuclear cells (PBMCs) from patients
with active SLE and SSc and in healthy subjects.2,3 Expression of a spectrum
of genes that constitutes an “IFN signature” is the most significant result from
these studies and indicates that either type I or type II IFNs may be dominant
among the pathogenic mediators involved in lupus. The link between IFNs
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and SSc pathogenesis is also supported by observations of several cases of
IFN-induced severe Raynaud’s phenomenon4 and of some cases of progres-
sion to a full-blown picture of SSc.5 Moreover, a clinical trial performed to
evaluate the possible antifibrotic action of -IFN in patients with early and dif-
fuse SSc failed to show any benefit from treatment. On the contrary, in patients
receiving -IFN, there was a significant worsening of lung function test com-
pared to placebo-treated patients, and more withdrawals due to lack of efficacy
and deaths.6 These observations suggest that IFN may have a deleterious effect
on the onset and the evolution of SSc.
THE IFI-200/HIN-200 GENE FAMILY
One family of IFN-inducible genes is the IFI-200/HIN-200 gene family,
which encodes evolutionarily related human (IFI16, MNDA, AIM2, and IFIX)
and murine proteins (Ifi202 a, Ifi202b, Ifi203, Ifi204, Ifi205/D3).7,8 The hu-
man and murine gene clusters are located on syntenic genomic regions of
chromosome 1 and probably stem from repeated gene duplications of one
ancestral gene. The IFI16, Ifi202b, and Ifi204 nuclear phosphoproteins are
relatively well characterized with respect to their role in IFN action: these pro-
teins are demonstrated to participate in the inhibition of cell cycle progression,
modulation of differentiation, and cell survival. Generally, IFI-200 proteins are
thought to act as scaffolds to assemble large protein complexes involved in the
regulation of transcription. The HIN-200 proteins contain at least a 200-amino
acid repeat that constitutes the HIN domain, which is always near the C ter-
minus. The common domain architecture PYD-HIN of these protein families
basically consists of one or two copies of the HIN domain and an N-terminal
PYD domain, also named PAAD, DAPIN, or PYRIN domain after the pro-
tein pyrin/marenostrin, the product of the familial Mediterranean fever gene.9
The PYD domain is frequently found in regulators of inflammatory immune
responses and apoptosis.
In the human IFI16 protein the PYD domain is followed by two copies of a
HIN domain. These are separated by a serine–threonine–proline (S/T/P)-rich
spacer region. The size of the spacer region in IFI16 is regulated by mRNA
splicing and can contain one, two, or three copies of the highly conserved
56-aa S/T/P/ domain. Three IFI16 isoforms (designated A, B, and C) arise due
to alternative RNA splicing in the exons encoding the S/T/P domain.10 The
200-amino-acid regions are unique to the HIN-200 proteins and contain no
known functional motifs that could provide some clue to their physiological
relevance. However, within the HIN-200 domains, there are stretches of amino
acids, such as MFHATVAT, which exhibit almost complete identity across the
A and B domains of all family members, and have been implicated in mediating
protein–protein interactions and dimerization.
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MOLECULAR MECHANISMS INVOLVED IN IFI16-INDUCED
IMMUNE DYSREGULATION
IFI16 overexpression can result in decreased cell proliferation and a block
in the cell cycle progression at the G1-S phase transition. A large body of evi-
dence indicates that p53 and pRb are indeed involved in IFI16-mediated growth
arrest. Overexpression of human papillomavirus 16 E6 and E7 oncoproteins
inactivating p53 and pRb, respectively, inhibited the growth-suppressive ef-
fects of IFI16.11 Prostate cancer cell lines expressing functional p53 and pRb
were significantly more sensitive to the antiproliferative activity of IFI16.12
The interaction of IFI16 with p53 in the nucleoplasm results in its stabiliza-
tion and transcriptional activation of the p53-responsive bax promoter and
expression of p53 target genes, such as p21 and HDM2.13 Consistent with
these observations, siRNA-mediated knockdown of IFI16 in human fibrob-
lasts suppressed p53-mediated transcription of p21WAF/CIP11 and Gadd45 pro-
moters and resulted in downregulated p21WAF1/CIP1 protein levels.12 IFI16 has
been identified as an essential growth-specific effector of the cell extrinsic
growth–inhibitory pathway of Ras/Raf signaling in medullary thyroid carci-
noma cells.14 Finally, IFI16 expression has been found deregulated in several
forms of human cancer.12,13,15 Evaluation of some features of in vitro angiogen-
esis, namely chemotaxis, Matrigel invasion, tube morphogenesis, and cell cycle
progression, has demonstrated that IFI16 overexpression impairs tube morpho-
genesis and proliferation of human endothelial cells.11 Altogether these results
point to a role for IFI16 in the regulation of cell growth, differentiation, and
angiogenesis.
IFI16 is expressed in CD34+ myeloid precursor cells and remains strongly
expressed within monocyte precursors, peripheral blood monocytes, and
throughout lymphoid development.16 However, IFI16 is not expressed in ma-
ture macrophages, nor is it found in cells of the erythroid and polymorphonu-
clear lineages. Following IFN-treatment, IFI16 localizes within the nucleolus
and the nucleoplasm of human cells as shown by both confocal microscopy
and immunoblotting of nuclear proteins. This nuclear import is mediated by
a bipartite nuclear localization sequence (NLS) located at the N terminus
of the protein. It has recently become evident that some HIN-200 proteins
are also present in nonhemopoietic tissues. Immunohistochemical analysis of
IFI16 expression in normal human tissues revealed that it is expressed in a
highly restricted pattern in selected cells within certain organs.17,18 IFI16 was
found in epithelial cells of the skin, gastrointestinal tract, urogenital tract, and
glands and ducts of breast tissues. Prominent IFI16 expression was seen in
stratified squamous epithelia, particularly intense in basal cells in the prolif-
erating compartments, whereas it gradually decreases in a more differentiated
suprabasal compartment. In the underlying dermis, staining of connective tis-
sue was restricted to scattered fibroblasts. In addition, all vascular endothe-
lial cells from both blood and lymph vessels strongly expressed IFI16. This
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physiological expression of IFI16 in endothelial cells and in stratified squa-
mous epithelia, such as skin, both of which are targets for the main clinical
manifestations of autoimmune diseases, indicated that IFI16 may be involved
in the early steps of inflammation by modulating endothelial and keratinocyte
cell function. Consistent with this hypothesis, transduction of IFI16 into
human umbilical vein endothelial cells (HUVECs) with a herpes simplex
virus-derived replication-defective vector efficiently suppressed formation of
capillary-like structures in vitro, and cell cycle progression associated with
cell death.11 Moreover, recent data obtained in our laboratory revealed that
IFI16-overexpressing HUVECs displayed an increase in expression of genes
involved in immunomodulation, cell growth, and apoptosis (unpublished data).
IFI16 triggered the expression of genes encoding adhesion molecules, such as
intracellular adhesion molecule-1 (ICAM-1) and E-selectin, or chemokines,
such as interleukin-8 (IL-8) and monocyte chemoattractant protein-1 (MCP-1).
Finally, treatment of cells with small interfering RNA (siRNA) target-
ing IFI16 significantly inhibited ICAM-1 induction upon IFN- treat-
ment, demonstrating that IFI16 is required for proinflammatory gene stimu-
lation.
Transcriptional regulation by type I and II IFN is a classic feature of the HIN-
200 gene cluster, but it is also evident that these genes can be induced by an array
of cytokines and differentiating agents. Several reports describe the induction
of HIN-200 proteins by other factors; Ifi202b was upregulated by platelet-
derived growth factor (PDGF), IL-6, and under reduced serum conditions.19–21
Ifi205 gene expression was induced by proinflammatory agents, such as LPS,
tumor necrosis factor- (TNF-), and PDGF.22,23 In HL-60 cells, IFI16 was
induced by dimetylsulfoxide, retinoic acid, and 1,25-dihydroxy vitamin D3.24
According to these findings, we reported that IFI16 is stimulated in HUVECs
by oxidative stress.25 We found that H2 O2 produced rapid accumulation of
IFI16, indicating that IFI16 may be involved in the response of endothelial
cells to oxidative stress. Regulation of IFI16 accumulation by H2 O2 appears
to be the result of its redox activity, as other compounds known to generate
ROS intracellularly caused an IFI16 increase as well. Moreover, we analyzed
whether its expression could be modulated by proinflammatory cytokines as
well. To this end, HUVECs were treated with a panel of either proinflammatory
cytokines including IL-1, and TNF- or anti-inflammatory cytokines, such
as IL-4, IL-10, IL-13, and IL-17. Total cell extracts were prepared at 24 h after
treatment and assessed for IFI16 expression by Western blotting. As expected,
IFI16 expression was strongly induced by the known inducers, such as IFN-,
-, and - (FIG. 1, lanes 6–8). Treatment with both proinflammatory molecules
resulted in a significant induction of IFI16 protein, already present at the lowest
cytokine concentrations used (lanes 2–5). In contrast, upon treatment with anti-
inflammatory cytokines, no significant variation of the IFI16 expression levels
in comparison to the basal level of untreated cells was observed (lanes 9–12).
This finding, together with the observation that IFI16 triggers expression of
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FIGURE 1. Modulation of IFI16 protein levels by cytokines in primary human endothe-
lial cells. HUVECs (2.5 × 104 cells/cm2), cultured in endothelial growth medium (EGM-2,
Clonetics, San Diego, CA, USA) containing 2% fetal bovine serum (FBS), were left un-
treated or incubated with human recombinant IL-1, TNF- (from Chemicon International,
Temecula, CA, USA), IFN- and IFN- (kindly provided by Antonio Ponzetto, Turin, Italy),
IFN- (kindly provided by Gianni Garotta, Geneva), IL-4, IL-10, IL-13 (Chemicon), and
IL-17 (R&D Systems, Minneapolis, MN, USA) at the indicated concentrations for 24 h.
Total cell lysates were collected and analyzed by immunoblotting with a rabbit polyclonal
antibody to IFI1617 or a mouse monoclonal antibody to actin (Chemicon) as loading control.
proinflammatory molecules, strongly indicates that it may play a crucial role
as inducer of the first steps of inflammation.
ANTI-IFI16 AUTOANTIBODIES IN SYSTEMIC
AUTOIMMUNE DISEASES
Vascular involvement in autoimmune connective tissue diseases is a com-
mon complication. SSc is associated with reactive angiogenesis, but in spite of
this, the disease finally leads to irreversible loss of capillaries.26 The reduction
in the number of capillaries is associated with endothelial swelling, basement
membrane thickening, and hyperplasia of the intima, with infiltration of in-
flammatory cells in the skin. It is therefore conceivable to hypothesize that
the release of nuclear proteins by endothelial cells from the cutaneous lesions,
undergoing apoptosis and necrosis, triggers the immune system, leading to the
production of autoantibodies. With this scenario in mind, one can hypothesize
a role for IFI16 in systemic autoimmune diseases, in which chronic inflam-
mation is involved.27 Accordingly, generation of mice congenic for the Nba2
locus (derived from the NZB strain of mice) interval on C57 BL/6 background,
coupled with gene expression analyses, has identified Ifi202, which belongs to
the murine IFI-200 gene family, as a candidate for lupus susceptibility.28 These
studies also showed that increased expression of Ifi202 in splenic cells (both
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B and T cells) correlated with splenomegaly and autoantibody production in
female mice.
Several groups have evaluated the presence of anti-IFI16 antibodies in au-
toimmune disease patients (TABLE 1).29 In 1994 Seelig et al.30 first detected
anti-IFI16 antibodies in a serum positive for antinuclear antibodies (ANAs),
anti-SSA/Ro, and anti-SSB/La autoantibodies. By immunoblotting analysis on
recombinant IFI16 expressed as MS2-polymerase fusion protein, these inves-
tigators also reported the presence of anti-IFI16 antibodies in 29% of sera
obtained from 374 SLE patients. With a different technique, such as serologi-
cal analysis of antigens by recombinant cDNA expression cloning (SEREX),
Uchida et al.31 detected anti-IFI16 antibodies in 70% of patients suffering
from both primary and secondary Sjo¨gren’s syndrome (SjS). Moreover, in
a recent paper, we identified anti-IFI16 antibodies in 21% of SSc patients
by solid-phase enzyme-linked immunosorbent assay (ELISA), with a recom-
binant purified His-tagged IFI16 protein as antigen.32 By using anti-IFI16-
positive sera from SSc patients, we also found that the immunoblot tech-
nique appeared to be as specific as ELISA, but differed in sensitivity, very
likely because immunoblot detects antibodies directed against linear epitopes,
while ELISA detects either linear or conformational epitopes. No correlation
between anti-IFI16 autoantibody levels by ELISA and the intensity of im-
munoreactive bands was observed. Finally, anti-IFI16-positive sera seen by
immunoblotting, tested with both N-terminal and C-terminal fragments of
IFI16 as antigens, reacted with either the N-terminal and C-terminal frag-
ment or both of them, suggesting that there was a polyclonal immune response
against IFI16 in patients with SSc. A lower prevalence was found in other sys-
temic autoimmune diseases, such as rheumatoid arthritis (RA) (0–13%) and
scleroderma/polymyositis overlap syndrome (4%). Seelig et al.30 found that
the presence of anti-IFI16 autoantibodies was more frequent in anti-dsDNA-
positive sera from SLE patients, but no correlation was found between the
titer of anti-IFI16 and the presence of anti-dsDNA, other autoantibodies, such
as anti-RNP, anti-Sm, anti-SSA/Ro, and anti-SSB/La or with any particular
clinical manifestation. In contrast, in our report, by analyzing SSc sera we
demonstrated a strict association between anti-IFI16 reactivity and the cuta-
neous form of the disease, with patients in the limited cutaneous scleroderma
(lcSSc) category having higher anti-IFI16 IgG titers than patients with the
diffuse form (dcSSc).32 Surprisingly, anti-IFI16 antibody did not associate
with the presence of other serological markers of SSc, such as anti-Scl70
antibodies or ACA antibodies. For the differential diagnosis of the cutaneous
form of SSc, anti-IFI16 reactivity displayed lower sensitivity (28%) and higher
specificity (96%) than those found with either anti-Scl70 (95% and 67%, re-
spectively) or anticentromere (65% and 92%, respectively). We found no cor-
relation between anti-IFI16 autoreactivity and either disease duration, disease
severity, or disability and no association was found with any particular clinical
manifestation.
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TABLE 1. Prevalence of anti-IFI16 autoantibodies in autoimmune diseases
Method of detection
Study group Immunoblotting30 SEREX31 ELISA32
SLE 29% (374) 33% (15) 26% (100)
RA 0 (30) 13% (15) 4% (50)
SSc NT NT 21% (82)
PM/Scl 4% (26) NT NT
Primary SjS NT 82% (11) 50% (20)
Secondary SjS 36% (74) 63% (19) NT
Controls 0 (188) 0 (12) 5% (80)
NOTE: Percentage of positivity for anti-IFI16 autoantibodies in patients and healthy controls. The
numbers in parentheses indicate the number of cases tested.
SEREX = serological analysis of antigens by recombinant cDNA expression cloning;
ELISA = solid-phase enzyme-linked immunosorbent assay. SLE = systemic lupus erythematosus;
RA = rheumatoid arthritis; SSc = scleroderma; PM/Scl = polymyositis/scleroderma overlap; SjS =
Sjo¨gren’s syndrome. NT = not tested.
CONCLUSIONS
Although further studies are needed to confirm the diagnostic value of anti-
IFI16 antibodies, there is compelling evidence that they could work as a sup-
plementary marker of SSc. Moreover, our data suggest that combined use of
anti-IFI16 and ACA markers improves the sensitivity and specificity score to
discriminate lcSSc from dcSSc. In particular, the finding that anti-IFI16 posi-
tivity allowed us to detect lcSSc patients among the subgroup negative for both
ACA and anti-Scl70 reactivity strongly indicates that it can be a valuable tool
for the differential diagnosis of lcSSc in the double-negative patients.
Additionally, our observations provide a mechanism by which IFI16 up-
regulation by both IFN and inflammatory cytokines in endothelial cells may
contribute to the development of autoimmunity. Increased levels of IFI16 are
indeed correlated with triggering of proinflammatory molecules and cell death
by apoptosis, providing support for the idea that IFI16 could be an important
mediator of the chronic inflammation and vascular involvement in systemic
autoimmune diseases.
Altogether, these studies are likely to advance our knowledge of IFI16 patho-
genetic role in systemic autoimmune diseases, which will be helpful in con-
sidering new strategies for the diagnosis and treatment of these diseases.
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